Academic Journal
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
| العنوان: | The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study. |
|---|---|
| المؤلفون: | Van Obbergh, Florence, Knoops, Laurent, Devos, Timothy, Beguin, Yves, Graux, Carlos, Benghiat, Samantha, Kargar-Samani, Khalil, Bauwens, Deborah, Efira, André, Dubois, Christian, Springael, Cécile, Montfort, Luc, Connerotte, Thierry, Capron, Arnaud, Delannoy, André, Wallemacq, Pierre |
| المساهمون: | UCL - SSS/IREC/MONT-Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Unité de soins continus |
| المصدر: | Clinical Biochemistry, Vol. 50, no. 7-8, p. 452-454 (2017) |
| بيانات النشر: | Elsevier Inc. |
| سنة النشر: | 2017 |
| المجموعة: | DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| مصطلحات موضوعية: | Chronic myeloid leukemia, Imatinib mesylate, Therapeutic drug monitoring |
| الوصف: | This retrospective multicenter study in patients with chronic myeloid leukemia in chronic phase was undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice. Forty-one patients, with 47 imatinib plasma measurements, were analyzed during treatment with imatinib given at a fixed 400mg daily dose. A significant inverse relationship of imatinib concentration with the patients' weight was observed (Pearson's test: p=0.02, R(2)=0.1). More interestingly, patients with poor response (switched to another tyrosine kinase inhibitor because of imatinib failure, or because of disease progression after an initial response) displayed a significantly lower mean imatinib concentration as compared to patients maintained on imatinib (822ng/mL vs 1099ng/mL; Student's t-test, p=0.04). Failure or disease progression occurred more often in patients in the lowest quartile of imatinib concentrations compared to patients in the highest quartile (p=0.02, logrank test). No correlation could be established with other biological or clinical parameter, including complete cytogenic response and major molecular response. IN CONCLUSION: in patients treated with imatinib at a fixed daily dose of 400mg, imatinib plasma concentrations decreased with increasing body weight and were lower in patients switched to another tyrosine kinase inhibitor due to imatinib failure. Systematic determination of imatinib plasma trough levels should be encouraged in such patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0009-9120 1873-2933 |
| Relation: | boreal:179680; http://hdl.handle.net/2078.1/179680; info:pmid/28017570; urn:ISSN:0009-9120; urn:EISSN:1873-2933 |
| DOI: | 10.1016/j.clinbiochem.2016.12.006 |
| الاتاحة: | http://hdl.handle.net/2078.1/179680 https://doi.org/10.1016/j.clinbiochem.2016.12.006 |
| Rights: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.CAD47D90 |
| قاعدة البيانات: | BASE |
| تدمد: | 00099120 18732933 |
|---|---|
| DOI: | 10.1016/j.clinbiochem.2016.12.006 |